NLS Pharmaceutics (NLS Pharmaceutics) Operating Cash Flow per Share : $-0.25 (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is NLS Pharmaceutics Operating Cash Flow per Share?

NLS Pharmaceutics's operating cash flow per share for the six months ended in Dec. 2023 was $-0.06. NLS Pharmaceutics's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.25.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -60.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was -52.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for NLS Pharmaceutics's Operating Cash Flow per Share or its related term are showing as below:

NLSP' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -253.2 Med: -67.75 Max: 48.8
Current: -60

During the past 7 years, NLS Pharmaceutics's highest 3-Year average Operating Cash Flow per Share Growth Rate was 48.80% per year. The lowest was -253.20% per year. And the median was -67.75% per year.

NLSP's 3-Year OCF Growth Rate is ranked worse than
91.9% of 1235 companies
in the Biotechnology industry
Industry Median: 3.3 vs NLSP: -60.00

NLS Pharmaceutics Operating Cash Flow per Share Historical Data

The historical data trend for NLS Pharmaceutics's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NLS Pharmaceutics Operating Cash Flow per Share Chart

NLS Pharmaceutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-0.02

-0.06

-1.26

-0.71

-0.25

NLS Pharmaceutics Semi-Annual Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial								-0.41	-0.48	-0.27	-0.19	-0.06

Competitive Comparison of NLS Pharmaceutics's Operating Cash Flow per Share

For the Biotechnology subindustry, NLS Pharmaceutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NLS Pharmaceutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NLS Pharmaceutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where NLS Pharmaceutics's Price-to-Operating-Cash-Flow falls into.

NLS Pharmaceutics Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

NLS Pharmaceutics's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-9.684	/	38.176
	=	-0.25

NLS Pharmaceutics's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-2.388	/	38.176
	=	-0.06

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.25

NLS Pharmaceutics Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of NLS Pharmaceutics's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

NLS Pharmaceutics (NLS Pharmaceutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NLS Pharmaceutics Ltd (NAS:NLSP) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

The Circle 6, Zurich, CHE, 8058

Website

https://www.nlspharma.com

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.